Skip to main content
Premium Trial:

Request an Annual Quote

Instrument Sales, Contracts Help Double Cepheid's Q3 Revenue

NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 53 percent as R&D spending rose 50 percent and its net loss increased around 19 percent.
 
Total receipts for the three months ended Sept. 30 increased to $36.3 million from $23.8 million year over year.
 
Cepheid said instrument sales rose around 118 percent to $15.9 million; reagent and disposable sales increased 18 percent to $18.1 million; contract revenues more than doubled to $2 million; and government and government-sponsored research revenue rose 125 percent to $289,000.
 
Cepheid CEO John Bishop said third-quarter results were driven by GeneXpert sales. He also suggested that tests the firm is developing in addition to its molecular-based test for methicillin-resistant Staphylococcus aureus will be in demand due to the "significant problem" of healthcare-acquired infections.
 
Cepheid’s R&D spending rose to $8.4 million from $5.6 million year over year.
 
The company said its third-quarter loss rose to $4.7 million from $4 million in the year-ago period.
 
Cepheid said it had around $8.3 million in cash and cash equivalents, and $33.1 million in marketable securities as of Sept. 30.
 
The company projected total revenues for fiscal year 2007 to be in the range of $124 million to $127 million.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.